Marek Jarema

Summary

Affiliation: Institute of Psychiatry and Neurology
Country: Poland

Publications

  1. ncbi request reprint Atypical antipsychotics in the treatment of mood disorders
    Marek Jarema
    III Department of Psychiatry, Institute of Psychiatry and Neurology, Warsaw, Poland
    Curr Opin Psychiatry 20:23-9. 2007
  2. ncbi request reprint Strategies of long-term treatment of psychotic disorders
    Marek Jarema
    III Department of Psychiatry, Institute of Psychiatry and Neurology, ul Sobieskiego 9, 02 9578 Warszawa, Poland
    Neuro Endocrinol Lett 28:13-26. 2007
  3. ncbi request reprint [Safety and efficacy of olanzapine versus perphenazine in patients with schizophrenia: results of multicenter, 18-week, double-blind clinical trial]
    Marek Jarema
    III Kliniki Psychiatrii IPiN w Warszawie
    Psychiatr Pol 37:641-55. 2003
  4. ncbi request reprint Herbal drug treatment
    Marek Jarema
    3rd Department of Psychiatry, Institute of Psychiatry and Neurology, Warszawa, Poland
    Neuro Endocrinol Lett 29:93-104. 2008
  5. ncbi request reprint [Acute psychiatric diseases]
    Joanna Meder
    Instytut Psychiatrii i Neurologii, Warszawa
    Psychiatr Pol 41:871-938. 2007
  6. doi request reprint Actigraphic monitoring of activity and rest in schizophrenic patients treated with olanzapine or risperidone
    Adam Wichniak
    Third Department of Psychiatry, Institute of Psychiatry and Neurology, Sobieskiego, Warsaw, Poland
    J Psychiatr Res 45:1381-6. 2011
  7. ncbi request reprint A few facts from the history of selected biological treatment methods in psychiatry
    Marek Jarema
    3rd Department of Psychiatry, Institute of Psychiatry and Neurology, Warszawa, Poland
    Neuro Endocrinol Lett 29:5-9. 2008
  8. ncbi request reprint [Subjective and objective evaluation of olanzapine treatment in schizophrenia]
    Marek Jarema
    III Kliniki Psychiatrycznej IPiN w Warszawie
    Psychiatr Pol 38:895-909. 2004
  9. ncbi request reprint [Current concepts of pharmacological treatment in schizophrenia]
    Marek Jarema
    III Kliniki Psychiatrycznej IPiN w Warszawie
    Psychiatr Pol 36:857-68. 2002
  10. ncbi request reprint [Pharmacological standards in schizophrenia treatment]
    Marek Jarema
    Grupa Robocza powołana przez Konsultanta Krajowego w dziedzinie psychiatrii dia opracowania Standardów Leczenia w Psychiatrii
    Psychiatr Pol 40:1171-205. 2006

Detail Information

Publications13

  1. ncbi request reprint Atypical antipsychotics in the treatment of mood disorders
    Marek Jarema
    III Department of Psychiatry, Institute of Psychiatry and Neurology, Warsaw, Poland
    Curr Opin Psychiatry 20:23-9. 2007
    ..Recent literature has been reviewed to show the potential use and usefulness of the atypical medications in patients suffering from depression or mania...
  2. ncbi request reprint Strategies of long-term treatment of psychotic disorders
    Marek Jarema
    III Department of Psychiatry, Institute of Psychiatry and Neurology, ul Sobieskiego 9, 02 9578 Warszawa, Poland
    Neuro Endocrinol Lett 28:13-26. 2007
    ..Such widely accepted standards are valuable tools to help to identify the most appropriate treatment for psychotic conditions, being not necessary adequate to patient's expectations and needs...
  3. ncbi request reprint [Safety and efficacy of olanzapine versus perphenazine in patients with schizophrenia: results of multicenter, 18-week, double-blind clinical trial]
    Marek Jarema
    III Kliniki Psychiatrii IPiN w Warszawie
    Psychiatr Pol 37:641-55. 2003
    ..The secondary objective was to assess the safety profile and clinical efficacy of the investigated drugs...
  4. ncbi request reprint Herbal drug treatment
    Marek Jarema
    3rd Department of Psychiatry, Institute of Psychiatry and Neurology, Warszawa, Poland
    Neuro Endocrinol Lett 29:93-104. 2008
    ..Some herbal formulations, such as St. John's wort, have been analyzed in clinical trials to estimate their real value. The use of other herbal medicines, such as Kava-kava, valerian, and Ginkgo biloba is discussed...
  5. ncbi request reprint [Acute psychiatric diseases]
    Joanna Meder
    Instytut Psychiatrii i Neurologii, Warszawa
    Psychiatr Pol 41:871-938. 2007
  6. doi request reprint Actigraphic monitoring of activity and rest in schizophrenic patients treated with olanzapine or risperidone
    Adam Wichniak
    Third Department of Psychiatry, Institute of Psychiatry and Neurology, Sobieskiego, Warsaw, Poland
    J Psychiatr Res 45:1381-6. 2011
    ..These changes are linked to negative and depressive symptoms...
  7. ncbi request reprint A few facts from the history of selected biological treatment methods in psychiatry
    Marek Jarema
    3rd Department of Psychiatry, Institute of Psychiatry and Neurology, Warszawa, Poland
    Neuro Endocrinol Lett 29:5-9. 2008
    ..Obviously, at present we are aware that these therapies should be considered far less efficient than modern psychotropic drugs; however, at the time when these methods were used, no other efficient treatment methods were available...
  8. ncbi request reprint [Subjective and objective evaluation of olanzapine treatment in schizophrenia]
    Marek Jarema
    III Kliniki Psychiatrycznej IPiN w Warszawie
    Psychiatr Pol 38:895-909. 2004
    ..The study was to evaluate objectively (by a physician) and subjectively (by the patients) the efficacy of 12-months olanzapine treatment of schizophrenic out-patients...
  9. ncbi request reprint [Current concepts of pharmacological treatment in schizophrenia]
    Marek Jarema
    III Kliniki Psychiatrycznej IPiN w Warszawie
    Psychiatr Pol 36:857-68. 2002
    ..It was stated that modern concepts of treatment of schizophrenia do not solely rely on the use of modern drugs, but include the multidirectional therapeutic actions with an active participation of the patient and his/her relatives...
  10. ncbi request reprint [Pharmacological standards in schizophrenia treatment]
    Marek Jarema
    Grupa Robocza powołana przez Konsultanta Krajowego w dziedzinie psychiatrii dia opracowania Standardów Leczenia w Psychiatrii
    Psychiatr Pol 40:1171-205. 2006
  11. ncbi request reprint [Second generation antipsychotics: similarities and differences]
    Marek Jarema
    III Kliniki Psychiatrycznej IPiN w Warszawie
    Psychiatr Pol 37:7-28. 2003
    ..At the same time it indicates that obvious differences in action exist inside the group...
  12. ncbi request reprint [Second generation of neuroleptics--expectations and the reality]
    Marek Jarema
    III Klinika Psychiatryczna Instytutu Psychiatrii i Neurologii w Warszawie
    Psychiatr Pol 36:209-16. 2002
    ..The careful selection of the drug and its dosage increases the possibility of good clinical improvement, but more wider use of these drugs is recommended in order to evaluate their practical usefulness...
  13. ncbi request reprint [The change of quality of life and clinical picture in schizophrenia]
    Marek Jarema
    III Kliniki Psychiatrycznej IPiN w Warszawie
    Psychiatr Pol 36:393-402. 2002
    ..After treatment the quality of life was significantly worse in patients who had distinct depression before treatment, than in those without depression or with only slight depression before treatment...